300529 Stock Overview
Engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Jafron Biomedical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.14 |
| 52 Week High | CN¥39.24 |
| 52 Week Low | CN¥21.76 |
| Beta | 0.59 |
| 1 Month Change | -15.01% |
| 3 Month Change | -25.60% |
| 1 Year Change | -2.89% |
| 3 Year Change | -47.99% |
| 5 Year Change | -64.00% |
| Change since IPO | 170.52% |
Recent News & Updates
Recent updates
Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 02
Potential Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Not Without Risk
Jan 18Calculating The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Dec 30Jafron BiomedicalLtd (SZSE:300529) Is Reinvesting At Lower Rates Of Return
Dec 10Jafron BiomedicalLtd (SZSE:300529) Seems To Use Debt Rather Sparingly
Nov 22Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%
Oct 21Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce
Oct 02Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Sep 09The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence
Aug 25Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40
May 28A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
May 24Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge
May 08Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture
May 02Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Apr 13Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 22Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce
Mar 04Shareholder Returns
| 300529 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -10.4% | -0.8% | 0.2% |
| 1Y | -2.9% | -5.6% | 8.4% |
Return vs Industry: 300529 exceeded the CN Medical Equipment industry which returned -5.6% over the past year.
Return vs Market: 300529 underperformed the CN Market which returned 8.4% over the past year.
Price Volatility
| 300529 volatility | |
|---|---|
| 300529 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 7.0% |
| 10% most volatile stocks in CN Market | 10.7% |
| 10% least volatile stocks in CN Market | 4.3% |
Stable Share Price: 300529 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300529's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 2,797 | Fan Dong | www.jafroninternational.com |
Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases.
Jafron Biomedical Co.,Ltd. Fundamentals Summary
| 300529 fundamental statistics | |
|---|---|
| Market cap | CN¥17.14b |
| Earnings (TTM) | CN¥724.21m |
| Revenue (TTM) | CN¥2.48b |
23.7x
P/E Ratio6.9x
P/S RatioIs 300529 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300529 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.48b |
| Cost of Revenue | CN¥467.14m |
| Gross Profit | CN¥2.01b |
| Other Expenses | CN¥1.29b |
| Earnings | CN¥724.21m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.94 |
| Gross Margin | 81.17% |
| Net Profit Margin | 29.19% |
| Debt/Equity Ratio | 39.8% |
How did 300529 perform over the long term?
See historical performance and comparisonDividends
3.6%
Current Dividend Yield86%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/21 03:02 |
| End of Day Share Price | 2025/04/21 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jafron Biomedical Co.,Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Shuo Song | Citic Securities Co., Ltd. |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |